Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Antengene Approved to Start Trial of Oral CD73 Inhibitor for Solid Tumors

publication date: Feb 7, 2022

Shanghai Antengene was approved to start an Australian Phase I trial of ATG-037, an oral small molecule CD73 inhibitor, in patients with advanced or metastatic solid tumors. As a primary objective, the study will evaluate the safety and tolerability of ATG-037 as a monotherapy and in combination with an immune checkpoint inhibitor. It will also determine the appropriate dose for Phase II studies and assess preliminary efficacy. CD73 is a target because it generates adenosine, which suppresses the immune system in the tumor microenvironment. The trial is a first-in-human study of the candidate. More details....

Stock Symbol: (HK: 6996)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.